A citation-based method for searching scientific literature

Paulina Gonzalez-Latapi, Connie Marras. J Parkinsons Dis 2022
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


LRRK2 parkinsonism in Tunisia and Norway: a comparative analysis of disease penetrance.
Faycel Hentati, Joanne Trinh, Christina Thompson, Ekaterina Nosova, Matthew J Farrer, Jan O Aasly. Neurology 2014
35
50


G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.
Carles Gaig, María José Martí, Mario Ezquerra, Maria Jesús Rey, Adriana Cardozo, Eduardo Tolosa. J Neurol Neurosurg Psychiatry 2007
78
50


Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.
A J Hughes, S E Daniel, L Kilford, A J Lees. J Neurol Neurosurg Psychiatry 1992
50

Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques.
Javier Simón-Sánchez, José-Félix Martí-Massó, José Vicente Sánchez-Mut, Coro Paisán-Ruiz, Angel Martínez-Gil, Javier Ruiz-Martínez, Amets Sáenz, Andrew B Singleton, Adolfo López de Munain, Jordi Pérez-Tur. Mov Disord 2006
62
50

PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF-kappaB-independent manner.
Lirlândia P Sousa, Fernando Lopes, Douglas M Silva, Luciana P Tavares, Angélica T Vieira, Bárbara M Rezende, Aline F Carmo, Remo C Russo, Cristiana C Garcia, Cláudio A Bonjardim,[...]. J Leukoc Biol 2010
93
50

Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease.
Alicia Garrido, Enrique Santamaría, Joaquín Fernández-Irigoyen, Marta Soto, Cristina Simonet, Manel Fernández, Donina Obiang, Eduardo Tolosa, María-José Martí, Shalini Padmanabhan,[...]. Mov Disord 2022
1
100

Akt decreases lymphocyte apoptosis and improves survival in sepsis.
Ursula Bommhardt, Katherine C Chang, Paul E Swanson, Tracey H Wagner, Kevin W Tinsley, Irene E Karl, Richard S Hotchkiss. J Immunol 2004
105
50

LRRK2 Phosphorylation, More Than an Epiphenomenon.
Antoine Marchand, Matthieu Drouyer, Alessia Sarchione, Marie-Christine Chartier-Harlin, Jean-Marc Taymans. Front Neurosci 2020
17
50

AKT/PKB Signaling: Navigating the Network.
Brendan D Manning, Alex Toker. Cell 2017
50

The Role of PI3K/Akt and ERK in Neurodegenerative Disorders.
Sachchida Nand Rai, Hagera Dilnashin, Hareram Birla, Saumitra Sen Singh, Walia Zahra, Aaina Singh Rathore, Brijesh Kumar Singh, Surya Pratap Singh. Neurotox Res 2019
157
50

A breakdown in microglial metabolic reprogramming causes internalization dysfunction of α-synuclein in a mouse model of Parkinson's disease.
Jia Lu, Chenfei Wang, Xin Cheng, Ruizhi Wang, Xuehan Yan, Pengju He, Hongzhuan Chen, Zhihua Yu. J Neuroinflammation 2022
2
50

Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity.
Chin-Hsien Lin, Han-I Lin, Meng-Ling Chen, Tzu-Ting Lai, Li-Ping Cao, Matthew J Farrer, Ruey-Meei Wu, Cheng-Ting Chien. Hum Mol Genet 2016
37
50

LRRK2 and Rab10 coordinate macropinocytosis to mediate immunological responses in phagocytes.
Zhiyong Liu, Enquan Xu, Hien Tran Zhao, Tracy Cole, Andrew B West. EMBO J 2020
30
50

A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease.
Peter Holmans, Valentina Moskvina, Lesley Jones, Manu Sharma, Alexey Vedernikov, Finja Buchel, Mohamad Saad, Jose M Bras, Francesco Bettella, Nayia Nicolaou,[...]. Hum Mol Genet 2013
88
50

Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.
Nicolas Dzamko, Maria Deak, Faycal Hentati, Alastair D Reith, Alan R Prescott, Dario R Alessi, R Jeremy Nichols. Biochem J 2010
286
50

Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium.
Thomas Guttuso, Kelly L Andrzejewski, David G Lichter, Julie K Andersen. J Neurol Sci 2019
16
50

The PI3K/Akt signaling axis in Alzheimer's disease: a valuable target to stimulate or suppress?
Elham Razani, Atieh Pourbagheri-Sigaroodi, Ava Safaroghli-Azar, Anahita Zoghi, Mahsa Shanaki-Bavarsad, Davood Bashash. Cell Stress Chaperones 2021
11
50


LRRK2 in Parkinson disease: challenges of clinical trials.
Eduardo Tolosa, Miquel Vila, Christine Klein, Olivier Rascol. Nat Rev Neurol 2020
166
50

Inflammatory profile in LRRK2-associated prodromal and clinical PD.
Kathrin Brockmann, Anja Apel, Claudia Schulte, Nicole Schneiderhan-Marra, Claustre Pont-Sunyer, Dolores Vilas, Javier Ruiz-Martinez, Markus Langkamp, Jean-Christophe Corvol, Florence Cormier,[...]. J Neuroinflammation 2016
42
50

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.
Andrew B West, Darren J Moore, Saskia Biskup, Artem Bugayenko, Wanli W Smith, Christopher A Ross, Valina L Dawson, Ted M Dawson. Proc Natl Acad Sci U S A 2005
866
50

LRRK2 regulation of immune-pathways and inflammatory disease.
Rebecca L Wallings, Malú G Tansey. Biochem Soc Trans 2019
53
50

Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils.
Ying Fan, Andrew J M Howden, Adil R Sarhan, Pawel Lis, Genta Ito, Terina N Martinez, Kathrin Brockmann, Thomas Gasser, Dario R Alessi, Esther M Sammler. Biochem J 2018
79
50

Unraveling the multifaceted nature of the nuclear function of mTOR.
Alek S Torres, Marina K Holz. Biochim Biophys Acta Mol Cell Res 2021
5
50

R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils.
Ying Fan, Raja S Nirujogi, Alicia Garrido, Javier Ruiz-Martínez, Alberto Bergareche-Yarza, Elisabet Mondragón-Rezola, Ana Vinagre-Aragón, Ioana Croitoru, Ana Gorostidi Pagola, Laura Paternain Markinez,[...]. Acta Neuropathol 2021
15
50

Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.
Nicolas Dzamko, Dominic B Rowe, Glenda M Halliday. Mov Disord 2016
52
50


The inflammatory chemokine CXC motif ligand 16 triggers platelet activation and adhesion via CXC motif receptor 6-dependent phosphatidylinositide 3-kinase/Akt signaling.
Oliver Borst, Patrick Münzer, Sergios Gatidis, Eva-Maria Schmidt, Tanja Schönberger, Evi Schmid, Syeda T Towhid, Konstantinos Stellos, Peter Seizer, Andreas E May,[...]. Circ Res 2012
104
50

Hydrogen sulfide inhibits abnormal proliferation of lymphocytes via AKT/GSK3β signal pathway in systemic lupus erythematosus patients.
Yanfang Han, Fanqin Zeng, Guozhen Tan, Chuntao Yang, Hongfeng Tang, Yijin Luo, Jianqiang Feng, Hui Xiong, Qing Guo. Cell Physiol Biochem 2013
31
50

Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease.
Taye H Hamza, Cyrus P Zabetian, Albert Tenesa, Alain Laederach, Jennifer Montimurro, Dora Yearout, Denise M Kay, Kimberly F Doheny, Justin Paschall, Elizabeth Pugh,[...]. Nat Genet 2010
540
50

Rab GTPases as Physiological Substrates of LRRK2 Kinase.
Wongi Seol, Daleum Nam, Ilhong Son. Exp Neurobiol 2019
17
50


The Parkinson's disease-linked Leucine-rich repeat kinase 2 (LRRK2) is required for insulin-stimulated translocation of GLUT4.
Natalja Funk, Marita Munz, Thomas Ott, Kathrin Brockmann, Andrea Wenninger-Weinzierl, Ralf Kühn, Daniela Vogt-Weisenhorn, Florian Giesert, Wolfgang Wurst, Thomas Gasser,[...]. Sci Rep 2019
12
50

An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts.
Shalini Padmanabhan, Thomas A Lanz, Donal Gorman, Michele Wolfe, Alison Joyce, Carlos Cabrera, Rosemary Lawrence-Henderson, Najah Levers, Neal Joshi, Thong C Ma,[...]. J Parkinsons Dis 2020
21
50

Increased Levels of Rictor Prevent Mutant Huntingtin-Induced Neuronal Degeneration.
Jordi Creus-Muncunill, Laura Rué, Rafael Alcalá-Vida, Raquel Badillos-Rodríguez, Joan Romaní-Aumedes, Sonia Marco, Jordi Alberch, Isabel Perez-Otaño, Cristina Malagelada, Esther Pérez-Navarro. Mol Neurobiol 2018
8
50

Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.
Jack D Scott, Duane E DeMong, Thomas J Greshock, Kallol Basu, Xing Dai, Joel Harris, Alan Hruza, Sarah W Li, Sue-Ing Lin, Hong Liu,[...]. J Med Chem 2017
79
50

PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum.
A Saavedra, J M García-Martínez, X Xifró, A Giralt, J F Torres-Peraza, J M Canals, M Díaz-Hernández, J J Lucas, J Alberch, E Pérez-Navarro. Cell Death Differ 2010
42
50

Inflammation and immune dysfunction in Parkinson disease.
Malú Gámez Tansey, Rebecca L Wallings, Madelyn C Houser, Mary K Herrick, Cody E Keating, Valerie Joers. Nat Rev Immunol 2022
39
50

LRRK2 is involved in the pathogenesis of system lupus erythematosus through promoting pathogenic antibody production.
Meiyu Zhang, Chengcheng Yao, Jun Cai, Shuai Liu, Xia-Nan Liu, Yingying Chen, Shujun Wang, Ping Ji, Meng Pan, Zizhen Kang,[...]. J Transl Med 2019
14
50

Akt signal transduction dysfunction in Parkinson's disease.
Suzanne Timmons, Meghan F Coakley, Aileen M Moloney, Cora O' Neill. Neurosci Lett 2009
129
50

Elevated In Vitro Kinase Activity in Peripheral Blood Mononuclear Cells of Leucine-Rich Repeat Kinase 2 G2019S Carriers: A Novel Enzyme-Linked Immunosorbent Assay-Based Method.
Katerina Melachroinou, Min Suk Kang, Christopher Liong, Sushma Narayan, Najah Levers, Neal Joshi, Katie Kopil, Samantha J Hutten, Marco A S Baptista, Shalini Padmanabhan,[...]. Mov Disord 2020
14
50

I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3β signaling pathway.
Etsuro Ohta, Tomoko Nihira, Akiko Uchino, Yoichi Imaizumi, Yohei Okada, Wado Akamatsu, Kayoko Takahashi, Hideki Hayakawa, Makiko Nagai, Manabu Ohyama,[...]. Hum Mol Genet 2015
47
50

New Insights and Implications of Natural Killer Cells in Parkinson's Disease.
Kelly B Menees, Jae-Kyung Lee. J Parkinsons Dis 2022
3
50

Inflammasome Activation in Parkinson's Disease.
Shannon Jewell, Ashane M Herath, Richard Gordon. J Parkinsons Dis 2022
1
100


Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson's Disease.
Milan Zimmermann, Kathrin Brockmann. J Parkinsons Dis 2022
1
100

Age-Related Adaptive Immune Changes in Parkinson's Disease.
Antonina Kouli, Caroline H Williams-Gray. J Parkinsons Dis 2022
1
100

Inflammatory Animal Models of Parkinson's Disease.
Juan García-Revilla, Antonio J Herrera, Rocío M de Pablos, José Luis Venero. J Parkinsons Dis 2022
1
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.